Pacira BioSciences, Inc. filed post-effective amendments to thirteen Form S-8 registration statements on November 17, 2026, deregistering all unsold shares previously registered under its employee equity and stock purchase plans following the completion of its merger with Viatris Inc.

Key Highlights

  • Thirteen registration statements terminated: Post-effective amendments were filed to deregister unsold shares under Registration Statement Nos. 333-175101 through 333-297971.
  • Merger completed November 17, 2026: Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris Inc., merged with and into Pacira BioSciences, with Pacira surviving as a wholly owned subsidiary of Viatris.
  • Merger Agreement dated October 8, 2026: The transaction was governed by an Agreement and Plan of Merger among Pacira BioSciences, Viatris Inc., and Peach Purchaser Sub Inc.
  • All offerings and sales terminated: According to the filing, the registrant has terminated all offerings and sales pursuant to the registration statements as a result of the merger.
  • No remaining registered shares: The filing states that after giving effect to these post-effective amendments, "there will be no remaining Shares registered by the Company pursuant to the Registration Statements."
  • Plans covered include multiple equity programs: Affected plans span the 2007 Stock Option/Stock Issuance Plan, the Amended and Restated 2011 Stock Incentive Plan, the Amended and Restated 2014 Employee Stock Purchase Plan, and the Amended and Restated 2014 Inducement Plan.

Pacira BioSciences Closes Out Equity Plan Registrations Following Viatris Acquisition

Pacira BioSciences, Inc., a Delaware corporation headquartered at 2000 Sierra Point Parkway, Suite 900, Brisbane, California, filed post-effective amendments on November 17, 2026, to terminate thirteen Form S-8 registration statements covering shares reserved for employee equity compensation plans. The filing was signed by Michael Rainerman, President of Pacira BioSciences, Inc.

According to the filing, the deregistration was triggered by the completion of the merger contemplated under the Agreement and Plan of Merger, dated October 8, 2026, by and among the registrant, Viatris Inc., and Peach Purchaser Sub Inc. The filing states that on November 17, 2026, Peach Purchaser Sub Inc. merged with and into Pacira BioSciences, with Pacira surviving the merger as a wholly owned subsidiary of Viatris. The filing describes Viatris as a Delaware corporation and Peach Purchaser Sub Inc. as a Delaware corporation and a wholly owned subsidiary of Viatris.

The registration statements being terminated covered shares originally registered across multiple filings dating back to June 23, 2011. The shares were registered under several named plans, including the Pacira Pharmaceuticals, Inc. 2007 Stock Option/Stock Issuance Plan, the Pacira BioSciences, Inc. Amended and Restated 2011 Stock Incentive Plan, the Pacira BioSciences, Inc. Amended and Restated 2014 Employee Stock Purchase Plan, and the Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan. All shares registered but remaining unsold as of November 17, 2026 are removed from registration by these amendments. The registrant noted that the amendments fulfill undertakings it had made in the original registration statements to remove unsold shares by post-effective amendment upon termination of the offerings.

What Was Disclosed

Pacira BioSciences filed post-effective amendments to thirteen S-8 registration statements to deregister all unsold equity plan shares following the November 17, 2026, completion of its merger with Viatris Inc., after which Pacira became a wholly owned subsidiary of Viatris.